Charles Schwab’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-81,284
| Closed | -$1.22M | – | 3083 |
|
|
2016
Q2 | $1.22M | Buy |
81,284
+1,134
| +1% | +$14.6K | ﹤0.01% | 2282 |
|
|
2016
Q1 | $976K | Buy |
80,150
+8,877
| +12% | +$124K | ﹤0.01% | 2359 |
|
|
2015
Q4 | $1.13M | Sell |
71,273
-11,259
| -14% | -$177K | ﹤0.01% | 2338 |
|
|
2015
Q3 | $1.27M | Sell |
82,532
-117,180
| -59% | -$2.53M | ﹤0.01% | 2295 |
|
|
2015
Q2 | $4.86M | Sell |
199,712
-45,258
| -18% | -$1.08M | 0.01% | 1558 |
|
|
2015
Q1 | $5.7M | Sell |
244,970
-15,916
| -6% | -$421K | 0.01% | 1414 |
|
|
2014
Q4 | $6.55M | Sell |
260,886
-326
| -0.1% | -$9.56K | 0.01% | 1232 |
|
|
2014
Q3 | $8.12M | Buy |
261,212
+5,437
| +2% | +$147K | 0.01% | 982 |
|
|
2014
Q2 | $6.62M | Sell |
255,775
-368
| -0.1% | -$8.17K | 0.01% | 1170 |
|
|
2014
Q1 | $5.99M | Buy |
256,143
+1,380
| +0.5% | +$30.2K | 0.01% | 1193 |
|
|
2013
Q4 | $6.47M | Buy |
254,763
+14,226
| +6% | +$321K | 0.01% | 1054 |
|
|
2013
Q3 | $4.96M | Buy |
240,537
+167,505
| +229% | +$3.73M | 0.01% | 1195 |
|
|
2013
Q2 | $1.56M | Buy |
+73,032
| New | +$1.31M | ﹤0.01% | 1911 |
|
Charles Schwab's SGNT Position: Q3 2016 in Review
Charles Schwab sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 81,284 shares — an estimated $1.22M sold.
Charles Schwab first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $8.12M in Q3 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Charles Schwab reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Charles Schwab sold 81,284 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $1.22M.
- Charles Schwab first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Charles Schwab's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $8.12M in Q3 2014.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Charles Schwab's 13F filing for Q3 2016, filed 14 Nov 2016.